NG2 Stock Overview
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Neogen Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.00 |
| 52 Week High | US$21.60 |
| 52 Week Low | US$11.00 |
| Beta | 1.12 |
| 1 Month Change | -21.99% |
| 3 Month Change | -27.63% |
| 1 Year Change | -29.03% |
| 3 Year Change | -72.50% |
| 5 Year Change | -58.36% |
| Change since IPO | 416.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| NG2 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -9.1% | -5.0% | -2.0% |
| 1Y | -29.0% | -13.6% | -0.3% |
Return vs Industry: NG2 underperformed the German Medical Equipment industry which returned -11% over the past year.
Return vs Market: NG2 underperformed the German Market which returned -0.2% over the past year.
Price Volatility
| NG2 volatility | |
|---|---|
| NG2 Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NG2's share price has been volatile over the past 3 months.
Volatility Over Time: NG2's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 2,640 | John Adent | www.neogen.com |
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Neogen Corporation Fundamentals Summary
| NG2 fundamental statistics | |
|---|---|
| Market cap | €2.36b |
| Earnings (TTM) | €1.47m |
| Revenue (TTM) | €872.28m |
1,606x
P/E Ratio2.7x
P/S RatioIs NG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NG2 income statement (TTM) | |
|---|---|
| Revenue | US$929.24m |
| Cost of Revenue | US$452.39m |
| Gross Profit | US$476.85m |
| Other Expenses | US$475.28m |
| Earnings | US$1.57m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0072 |
| Gross Margin | 51.32% |
| Net Profit Margin | 0.17% |
| Debt/Equity Ratio | 28.3% |
How did NG2 perform over the long term?
See historical performance and comparison